Histološke karakteristike i markeri proliferacije i diferencijacije u mozgu pacova sa eksperimentalnim gliomom
Sažetak
Uvod/Cilj. Ćelijska linija C6 predstavlja kontinuiranu ćelijsku liniju glioma pacova i kao transplantabilna linija, često se koristi za indukciju in vivo modela primarnog moždanog tumora. Smatra se da po histološkim osobinama ili biološkom ponašanju ovaj eksperimentalni tumor odgovara humanom anaplastičnom astrocitomu gradusa II/III, koji karakteriše proliferativni i invazivni potencijal, kao i izražena ćelijska diferencijacija. Cilj ovog rada bio je da se odrede: makroskopska analiza mozgova pacova sa implantiranim tumorom u toku tumorogeneze, histološke karakteristike tumorskih ćelija indukovanog moždanog tumora i markeri proliferacije (proliferativni ćelijski nuklearni antigen – PCNA, citokeratin – CK 19) i diferencijacije (glialni fibrilatni kiseli protein – GFKP) u mozgu pacova sa implantiranim tumorom. Metode. Za određivanje histološke građe mozga sa implantiranim C6 ćelijama korišćeni su isečci mozga obojeni hematoksilin-eozinom ili krezil violet bojom, dok su drugi isečci imunohistohemijski obojeni na GFKP, citokeratin 19 i PCNA. Rezultati. Utvrđeno je da postoji statistički značajna razlika u težini između leve i desne hemisfere mozgova sa implantiranim tumorima u toku tumorogeneze već 7 dana od indukcije tumora. Tumor je bio celularnog tipa, sa izraženim pleomorfizmom ćelija i čestom hiperhromazijom nukleusa. Imunohistohemijsko bojenje na PCNA pokazalo je veliki broj pozitivnih ćelija posle 7, 14, i 21 dan od implantacije C6 ćelija. Ćelije pozitivne na CK 19 bile su prisutne u obe hemisfere mozga, a brojni GFAP pozitivni astrociti nađeni su oko mesta ubodne lezije. Zaključak. U eksperimentalnim uslovima ove studije gliom C6 nije pokazao značajnija odstupanja u smislu razvoja, kliničke simptomatologije i makroskopske anatomije od one koja je već opisana u literaturi.
Reference
Benda P, Lighthody J, Sato G, Levine L, Sweet W. Differentiated rat glial cell strain in tissue culture. Science 1968; 161(3839): 370−1.
Bullard DE, Schold SC, Bigner SH, Bigner DD. Growth and che-motherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol 1981; 40(4): 410−27.
Bissell MG, Rubinstein LJ, Bignami A, Herman MM. Characteristics of the rat C-6 glioma maintained in organ culture systems. Production of glial fibrillary acidic protein in the absence of gliofibrillogenesis. Brain Res 1974; 82(1): 77−89.
Bravo R, Frank R, Blundell PA, Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 1987; 326(6112): 515−7.
Garcia R, Coltrera MD, Gown AM. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. Am J Pathol 1989; 134(4): 733−9.
Koch PJ, Roop DR. The role of keratins in epidermal develop-ment and homeostasis-going beyond the obvious. J Invest Dermatol 2004; 123(5): 10−1.
Rutka JT, Smith SL. Transfection of human astrocytoma cells with glial fibrillary acidic protein complementary DNA analysis of expression proliferation and tumorogenticity. Cancer Res 1993; 53(15): 3624−31.
Perentes E, Rubinstein LJ. Recent applications of immunoperox-idase histochemistry in human neuro-oncology. An update. Arch Pathol Lab Med 1987; 111(9): 796−812.
Kleihues P, Burger PC, Scheithauer BW. The new WHO classifica-tion of brain tumours. Brain Pathol 1993; 3(3): 255−68.
Chicoine MR, Silbergeld DL. Invading C6 glioma cells maintain-ing tumorigenicity. J Neurosurgery 1995; 83(4): 665−71.
Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a compari-son between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29(4): 577−80.
Black PM. Brain tumors. Part 1. N Engl J Med 1991; 324(21): 1471−6.
Hiesiger EM, Voorhies RM, Basler GA, Lipschutz LE, Posner JB, Shapiro WR. Opening the blood-brain and blood-tumor bar-riers in experimental rat brain tumors: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow. Ann Neurol 1986; 19(1): 50−9.
Nomura Y, Kitamura Y. Inducible nitric oxide synthase in glial cells. Neurosci Res 1993; 18(2): 103−7.
Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 1998; 36(1): 91−102.
Auer RN, del Maestro RF, Anderson R. A simple and reproducible experimental in vivo glioma model. Can J Neurol Sci 1981; 8(4): 325−31.
Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005; 109(1): 93−108.
Fu Y, Du J, Yang R, Yin L, Liang A. Potential adenovirus-mediated gene therapy of glioma cancer. Biotechnol Lett 2010; 32(1): 11−8.
Chekhonin VP, Baklaushev VP, Yusubalieva GM, Pavlov KA, Uk-hova OV, Gurina OI. Modeling and immunohistochemical anal-ysis of C6 glioma in vivo. Bull Exp Biol Med 2007; 143(4): 501−9.
Yusubalieva GM, Baklaushev VP, Gurina OI, Tsitrin EB, Chekhonin VP. Immunochemical analysis of glial fibrillary acidic protein as a tool to assess astroglial reaction in experimental C6 glioma. Bull Exp Biol Med 2010; 149(1): 125−30.
Chekhonin VP, Baklaushev VP, Yusubalieva GM, Gurina OI. Tar-geted transport of 125I-labeled antibody to GFAP and AMVB1 in an experimental rat model of C6 glioma. Neu-roimmune Pharmacol 2009; 4(1): 28−34.
Vince GH, Bendszus M, Schweitzer T, Goldbrunner RH, Hildebrandt S, Tilgner J, et al. Spontaneous regression of experimental gli-omas: an immunohistochemical and MRI study of the C6 gli-oma spheroid implantation model. Exp Neurol 2004; 190(2): 478−85.